Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cyclopharm Limited ( (AU:CYC) ) has provided an announcement.
Cyclopharm Limited has completed a two-tranche share placement first announced in early February, issuing a total of 14,736,842 new fully paid ordinary shares at $0.95 each to raise A$14 million before costs from institutional investors. The company confirmed that the second tranche of 5,263,158 shares was issued without a prospectus under statutory provisions, and stated it remains compliant with its financial reporting and continuous disclosure obligations, with no undisclosed price-sensitive information.
The capital raising strengthens Cyclopharm’s balance sheet and provides additional funding flexibility for its nuclear medicine and diagnostic imaging operations, potentially supporting growth initiatives and market expansion. Institutional investor support at the placement price underscores confidence in the company’s strategy and regulatory standing, which may have implications for liquidity and valuation in the listed market.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an Australian healthcare company focused on nuclear medicine and diagnostic imaging technology, best known for its Technegas system used in lung ventilation imaging. The company targets hospitals and imaging centres globally, supplying specialised radiopharmaceutical products and related services to support respiratory and other diagnostic procedures.
Average Trading Volume: 145,437
Technical Sentiment Signal: Sell
Current Market Cap: A$93.62M
See more data about CYC stock on TipRanks’ Stock Analysis page.